文献速递湿疹皮炎与荨麻疹

开发新型患者报告结局工具评估肤色人群特应性皮炎相关色素沉着异常与皮肤干燥

Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colour.
PubMed 文献 · Br J Dermatol · 2025-01-01

本研究针对肤色人群特应性皮炎(AD)相关的皮肤干燥和色素沉着异常,开发并内容验证了患者报告结局(PRO)问卷。通过文献回顾、专家咨询及15例中重度AD肤色患者的混合访谈,最终形成X-AD(1个11点NRS评估干燥严重度,2个0-4分口头评分评估困扰)和D-AD(2个11点NRS评估色素沉着严重度,2个条目评估外观困扰)问卷,患者认为问卷相关、易于理解且回忆期合适。

要点

  • X-AD问卷含1个11点NRS评估干燥严重度,2个0-4分条目评估过去一周干燥外观和感觉的困扰。
  • D-AD问卷含2个11点NRS评估色素沉着严重度,2个条目评估过去一周色素沉着外观的困扰。
  • 问卷在15例中重度AD肤色患者中内容效度良好,但需心理测量学验证以评估测量属性并制定评分解释指南。

核心结论

  • X-AD和D-AD问卷能全面捕捉肤色人群AD相关皮肤干燥和色素沉着异常的患者体验,内容效度良好。
  • 研究支持问卷的初步开发符合监管指南和最佳实践,但尚需心理测量学验证以评估测量属性并制定评分解释指南。

研究设计与样本

  • 研究类型为问卷开发与内容验证研究,包括针对性文献回顾、与3名临床专家的建议会议,以及与15例肤色中重度AD患者(成人及青少年)的混合概念引出和认知 debriefing 访谈。

主要发现

  • 15例肤色AD患者[47%为女孩/女性;平均(SD)年龄33.3(21.2)岁]报告问卷与其AD体验相关、回忆期合适、易于理解且易于选择有意义的回答。
  • 最终X-AD由1个11点数字评定量表(NRS)评估干燥严重度和2个条目(0-4分口头评定量表)评估过去一周干燥外观和感觉相关困扰组成。
  • 最终D-AD由2个11点NRS条目评估色素沉着严重度和2个条目评估过去一周色素沉着外观相关困扰组成。

关键数值与推荐

  • X-AD的干燥严重度采用11点NRS评估;干燥相关困扰采用2个条目,0-4分口头评定量表,回忆期为过去一周。
  • D-AD的色素沉着严重度采用2个11点NRS条目评估;色素沉着相关困扰采用2个条目评估过去一周外观困扰。

临床怎么用

  • X-AD和D-AD问卷可用于临床研究中评估肤色AD患者的皮肤干燥和色素沉着异常体验,但当前仅完成内容验证,尚不能用于评分解释或临床决策。

局限性

  • 研究仅进行了内容验证,尚未开展心理测量学验证以评估问卷的测量属性。
  • 研究样本量较小(15例患者),且仅纳入中重度AD的成人和青少年肤色患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence and burden of atopic dermatitis (AD) are disproportionately high in people with skin of colour. Previous research has shown that the risk of xerosis and/or dyspigmentation is heightened in this population and may be more bothersome. However, no patient-reported instruments have been developed specifically for these disease sequelae in patients with skin of colour. OBJECTIVES: To develop and perform content validation of patient-reported outcome (PRO) questionnaires to assess AD-related xerosis and dyspigmentation in patients with skin of colour. METHODS: A targeted literature review was conducted to understand and identify AD-related disease sequelae and quality-of-life impacts relevant to patients with skin of colour and any instruments used to assess AD in the target population. Two draft PRO questionnaires assessing xerosis (X-AD) and dyspigmentation (D-AD) were developed and refined following advice meetings with three clinical experts. Questionnaire content validity was explored during hybrid concept elicitation and cognitive debriefing interviews with 15 adult and adolescent patients with skin of colour who have moderate-to-severe AD. RESULTS: Ten concept-focused articles, 3 websites, 17 labels, 1 U.S. Food and Drug Administration compendium and 1 clinical trial confirmed that xerosis and dyspigmentation are important AD-related disease sequelae. Patients with skin of colour [47% girls/women; mean (SD) age 33.3 (21.2) years] reported that the questionnaires were relevant to their AD experience in an appropriate recall timeframe and were readily understood, and that meaningful responses were easy to select. The final X-AD consisted of one 11-point numerical rating scale (NRS) assessing xerosis severity and two items assessing the level of bother associated with xerosis appearance and feeling over the past week (0-4 verbal rating scale). The final D-AD consisted of two 11-point NRS items assessing dyspigmentation severity and two items assessing the level of bother associated with how dyspigmentation looked over the past week. CONCLUSIONS: The X-AD/D-AD questionnaires were well understood and effective in capturing the experiences of xerosis and dyspigmentation in the target population in an appropriate and comprehensive way. This study supports the initial development of the questionnaires in accordance with regulatory guidelines and best practices; however, psychometric validation is required to evaluate the properties of each questionnaire and develop score interpretation guidelines. Atopic dermatitis (or ‘AD’ for short) is a long-term, relapsing (‘comes and goes’) skin disease. It causes intense itching and dry, inflamed lesions. AD is one of the most common inflammatory skin diseases. It affects people of all races and ethnicities. However, people with skin of colour are more likely to have severe signs (what the doctor sees) and symptoms (what a patient experiences). Dry, scaly skin and changes in skin colour may be particularly bothersome to people with skin of colour. We aimed to better understand the experience of people with skin of colour who have AD. To measure the signs and symptoms of skin dryness and discoloration in people with skin of colour, we created two new questionnaires. Experts and patients helped improve the questionnaires. Three doctors who treat people with AD and 15 patients with skin of colour who have AD reviewed, updated and tested them. Our findings show that dryness and skin discoloration are important to patients with skin of colour who have AD. The new questionnaires use wording that connects with people's experiences.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hartford C, Alexis A, Wang Z, et al. Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colour. Br J Dermatol. 2025. PMID: 39792566. doi:10.1093/bjd/ljae494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。